EDAP TMS S.A.

Click Here To EMAIL INQUIRY
Contact: Mr. Marc Oczachowski - President
Web: http://www.edap-tms.com
E-Mail:
Address: Parc d'activités la Poudrette - Lamartine, 4, rue du Dauphine, Vaulx-en-Velin F-69120, France
Phone: +33-(472)-153 150 | Fax: +33-(472)-153 151 | Map/Directions >>

Profile: EDAP TMS S.A. develops, produces, markets and distributes minimally-invasive therapeutic solutions for urology. We specialize in therapeutic ultrasound. We provide minimally-invasive treatment for localized prostate cancer. Our Ablatherm® HIFU is a fully robotic device with innovative features that guarantee optimal safety and efficiency for each treatment. This minimally-invasive technology causes few sides effects and helps continue the patient's quality of life. Sonolithr i-sys electroconductive shock-wave lithotripter is ideal for public or private centers with moderate to high patient load. It is fully integrated & transportable. It features an exclusive intuitive localization system called stone locking system for a unique robotization level and clinical versatility for ESWL & endourology procedures. Its exclusive shock-wave generator features a penetration depth up to 210 mm, so that obese patients can benefit from painless, safe and efficient ESWL. The 290 mm generator diameter combined with a maximum shock wave entry area on patient's skin of 914mm² (beam angle at F2 is 80°), produces very little pressure on the patient’s skin resulting in a pain-free treatment. Treatment can be done without any anesthesia.

The company has revenues of USD 10-25 Million, has ~100 employees and is ISO 9001, CE certified.

7 Products/Services (Click for related suppliers)

• Dual Isocentric and Motorized Imaging Systems

• Electroconductive Shock-wave Lithotripters

• Intuitive Localization Systems

• Microwave Hyperthermia System (FDA Code: MEQ)

• Minimally Invasive Probe for Localized Prostate Cancer

• Prostate-Specific Antigen for Management of Prostate Cancers (FDA Code: LTJ / 866.6010)

A tumor-associated antigen immunological test system is a device that consists of reagents used to qualitatively or quantitatively measure, by immunochemical techniques, tumor-associated antigens in serum, plasma, urine, or other body fluids. This device is intended as an aid in monitoring patients for disease progress or response to therapy or for the detection of recurrent or residual disease.

• Urological Extracorporeal Shock-wave Lithotriptor (FDA Code: LNS / 876.5990)

An extracorporeal shock wave lithotripter is a device that focuses ultrasonic shock waves into the body to noninvasively fragment urinary calculi within the kidney or ureter. The primary components of the device are a shock wave generator, high voltage generator, control console, imaging/localization system, and patient table. Prior to treatment, the urinary stone is targeted using either an integral or stand-alone localization/imaging system. Shock waves are typically generated using electrostatic spark discharge (spark gap), electromagnetically repelled membranes, or piezoelectric crystal arrays, and focused onto the stone with either a specially designed reflector, dish, or acoustic lens. The shock waves are created under water within the shock wave generator, and are transferred to the patient's body using an appropriate acoustic interface. After the stone has been fragmented by the focused shock waves, the fragments pass out of the body with the patient's urine.